Bicitra (Sodium Citrate and Citric Acid Oral Solution)
Bicitra is indicated primarily for alkalinizing urine to prevent calcium oxalate and uric acid kidney stones in patients with hypocitraturia, and should be dosed at 10-30 mEq (15-30 mL) three times daily after meals, diluted in water. 1
Indications
Bicitra serves as an alkalinizing agent for:
- Prevention of calcium oxalate nephrolithiasis in hypocitraturic patients (moderate-strength evidence shows citrates reduce composite stone recurrence with RR 0.25) 2
- Uric acid stone prevention through urinary alkalinization 3
- Distal renal tubular acidosis with hypercalciuria 3, 4
The evidence base strongly supports citrate therapy for stone prevention. In randomized trials, citrates demonstrated a 75% relative risk reduction for stone recurrence compared to placebo/control 2. The number needed to treat is approximately 2-3 patients over 3 years to prevent one stone recurrence 5.
Dosing Regimen
Standard adult dosing: 10-30 mEq (15-30 mL) three times daily after meals 1
Pediatric dosing for distal RTA: Start at 2 mEq/kg/day divided three times daily, titrate up to 4 mEq/kg/day as needed to normalize urinary parameters 4
Critical administration points:
- Must be diluted adequately with water before ingestion 1
- Take after meals to minimize gastrointestinal side effects 1
- The liquid formulation (Bicitra) avoids tablet-related issues like residue in stool and swallowing difficulties seen with potassium citrate tablets 6
Contraindications
Absolute contraindications:
- Severe renal impairment with oliguria or anuria 1
- Hyperkalemia (though Bicitra contains sodium, not potassium) 3
- Concurrent aluminum-based antacid use 1
- Active urinary tract infection with urease-producing organisms 3
- Peptic ulcer disease or active gastritis 3
Relative contraindications requiring caution:
- Cardiac failure 1
- Hypertension (due to sodium content: 1 mEq Na+ per mL) 1
- Peripheral or pulmonary edema 1
- Toxemia of pregnancy 1
- Hypocalcemia (risk of alkalosis) 1
Monitoring Requirements
Essential monitoring parameters:
- Serum electrolytes (particularly bicarbonate) periodically in patients with renal disease 1
- Serum calcium to avoid complications from alkalosis in hypocalcemic patients 1
- Urinary pH - target 6.5-7.0 for calcium oxalate prevention, 6.5-7.5 for uric acid stones 2
- 24-hour urine citrate levels to assess therapeutic response 7
- Renal function in patients with impaired kidney function 1
Adherence monitoring is critical - pharmacy-based measures (percentage of days covered ≥80%) correlate better with clinical outcomes than biochemical markers alone 7.
Adverse Effects
Common adverse effects:
- Generally well-tolerated in patients with normal renal function 1
- Gastrointestinal effects: Mild diarrhea (saline laxative effect), nausea, abdominal discomfort 1, 6
- Metabolic alkalosis - particularly in patients with abnormal renal mechanisms 1
Serious but rare complications:
- Development of alkalosis in presence of hypocalcemia 1
- Hypernatremia and fluid overload in susceptible patients 1
Key advantage over potassium citrate tablets: Bicitra liquid formulation avoids tablet-related problems (throat irritation, foreign body sensation, tablet residue in stool) that represent the most common adverse events reported with solid potassium citrate formulations 6.
Clinical Pearls
The liquid formulation makes Bicitra particularly useful for patients who cannot tolerate tablets or have swallowing difficulties. However, the high sodium content (1 mEq/mL) makes it less suitable than potassium citrate for hypertensive patients or those requiring sodium restriction. For stone prevention specifically, potassium citrate remains the preferred first-line agent when sodium restriction is needed 2, 3.
Dilution with water and post-meal administration are non-negotiable to prevent gastrointestinal upset 1. Monitor for signs of volume overload in at-risk populations given the substantial sodium load.